Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have to correct myself, had old figures in my head.
According to the Nasdaq website we are at 10.83%.
Still not too great, but looking forward to the update!
Institutional ownership is now at 6%?
Note as well that a Law firm replied, not the usual IR 3d party
How do you know that every Anavex shareholder has email or a phone? It is a valid presumption, maybe
Got this back from IR regarding "TA gagging"
I can confirm that I have required that the transfer agent comply with Regulation FD.
--------------------------
Sent from my BlackBerry Wireless Handheld
This electronic message contains information from the law firm of K&L Gates LLP. The contents may be privileged and confidential and are intended for the use of the intended addressee(s) only. If you are not an intended addressee, note that any disclosure, copying, distribution, or use of the contents of this message is prohibited. If you have received this e-mail in error, please contact me at Clayton.Parker@klgates.com<mailto:Clayton.Parker@klgates.com>.-4
Regulation FD requires disclosure of information in a manner that provides equal access for all shareholders. This would include providing information on the number of outstanding shares.
--------------------------
Sent from my BlackBerry Wireless Handheld
Mice... enough said
Seriously?? Big pharma plot to suppress Anavex!
"Big Pharma is spending not only to Suppress Anavex Market Value ,,,,, But Anavex News? Big Pharma is spending ALOT! Don't listen to these delusional"
Missling is on the public record saying recently he is not interested to raise money at this stage.
If his statement is false, then there would a valid reason for SEC investigation. Why the hell would he open himself up to this crap, given the experience of being falsely accused before.
Get the facts straight: we are NOT down to 7 patients. Those on Donepzil are still continuing and providing the trial with safety and efficacy data.
Neither, only an attempt to influence retail shareholders and shake their shares.
And because it was posted on this board, it is a fact
The CEO is on the record saying he was not interested in raising money in the near future. He has cash for the next 12 months.
Should we now disbelieve him because statistics say he will have to dilute?
Of course he will need cash in 12 months from now. Easy statistic.
They gagged?
Who is they and where is the proof?
Long time since we heard anything about the magics of cannibonids. Does cure everything?
What mishandling of data?
Stop confusing how others have used scientific data release to further there short agenda with how the company handles data release.
Our phase 2 is appropriately powered to test the primary and secondary endpoints.
Let's hope Missling has learned from the 3 previous share price disasters post-data release...
One can hardly call the last data results as positive. Neutral as best. It has potential, but to be proven. Seems Biogen agrees.
don't forget sigma-1 !
Well it is very obvious who does not agree with management. Wondering why I would want to be Don Quichote and fight the windmills...
So yeah we're are the grant denials?
Which grants were denied?
I do not work on the assumption that grants are pre-announced in corporate presentation. They are not.
Absence of a pre-announcement does not mean SNGX will no longer apply and be awarded grants.
Easy to make statements, harder to back'em up with facts.
Yes it does. FDA wants more data on a disposable item from the delivery mechanism. Nothing related at all with the drug itself.
Read the article, not so positive either on AXON and their IPO.
Of course we know how much he likes to shout his love on Anavex! ;)
Anavex lover Jean Fonteneau is spreading his love for our Alzheimer "competitor" AXON:
https://medium.com/@jfindallas/the-axovant-ipo-saga-b6246c5a9a6d#.762lbzgx2
A very shallow dive gave me the exact reverse split ratio.
As for garbage, each to its own opinion. I differ.
And so does DARPA, MedImmune,...
Get your facts straight: reverse split was 1 to 4 and happened on June 6th 2014.
Fda wants more data on the disposable parts of the new electroporation device.
Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
PLYMOUTH MEETING, Pa. – October 24, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notification issued by the FDA to a trial sponsor to delay a proposed clinical trial or suspend an ongoing clinical trial. This study has not yet been initiated and has not enrolled or dosed subjects. Additionally, the hold does not pertain to any of Inovio’s other ongoing clinical studies.
Inovio anticipates receiving a formal letter with complete information from the FDA within 30 days. In its initial communication, the FDA has requested additional data to support the shelf-life of the newly designed and manufactured disposable parts of the CELLECTRA® 5PSP immunotherapy delivery device. Inovio is working diligently with the FDA to address its concerns and anticipates that the requested data will be available before the end of this year. Inovio estimates that the start of the phase III clinical program will be delayed until the first half of 2017 pending resolution of the FDA’s requests.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.
Possibly, time will tell.
This is different to last year as he was then referring to a partnership for a phase 3. The current cash is most surely far from sufficient to fund a p3. So will it be then LPC? a grant?
All I know he is saying something different then a year ago on a major issue, without an explenation to his shareholders.
He was on the record last year saying within the next 12 months. So either he can not deliver because nobody wants too or that the terms are not mutually agreeable.
Any case, he changed his tune.
Unrealistic:
Expecting a cure based on pooled data of 27 patients
Buyout based on this data
Miracle drug for all CNS diseases
FDA approval without a decent sized p3
Realistic:
Well designed p3 that can confirm efficacy
External funding for this p3 (grant or partner)
And come back to earth like a crashing meteorite. So far this pattern was there in November and July.
And we know what happens to our shareprice after positive data releases: plummeting.
Possible but untrue. As confirmed by dr Wilson.
I believe yesterday was one false rumour that led to a panic sell by some. Rumour denied by Wilson as bulletin fake noise.
Favorable efficacy, for me, means disease halt for a significant time, if it would show only slowdown then it could still be commercially viable, depending on the amount of weeks or months it can beat Donepzil.